Back to Search
Start Over
Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
- Source :
- Opuholi Ženskoj Reproduktivnoj Sistemy, Vol 17, Iss 2 (2021)
- Publication Year :
- 2021
- Publisher :
- Publishing House ABV Press, 2021.
-
Abstract
- The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life expectancy of patients. This review presents the features of the mechanism of action of CDK4/6 inhibitors, the most significant and updated results of large, randomized trials with ribociclib (MONALEESA-2, MONALEESA-3, and MONALEESA-7) assessing the efficacy and safety of combined endocrine therapy with various endocrine partners in a population of premenopausal women and menopausal patients. The prospects for the use of CDK4/6 inhibitors for therapy patients with visceral crisis are shown.
- Subjects :
- Oncology
monaleesa-7
medicine.medical_specialty
monaleesa-3
monaleesa-2
Population
Ribociclib
Disease
law.invention
combined endocrine therapy
Randomized controlled trial
law
Internal medicine
Medicine
Endocrine system
Pharmacology (medical)
Radiology, Nuclear Medicine and imaging
Progression-free survival
ribociclib
visceral crisis
education
education.field_of_study
business.industry
Endocrine therapy
Obstetrics and Gynecology
Gynecology and obstetrics
medicine.disease
Metastatic breast cancer
inhibitors cdk4/6
RG1-991
Surgery
business
Subjects
Details
- ISSN :
- 19998627 and 19944098
- Volume :
- 17
- Database :
- OpenAIRE
- Journal :
- Tumors of female reproductive system
- Accession number :
- edsair.doi.dedup.....9c534187eb741b3e63bfc34338c85cac